Product pipeline

Genmab has two products on the market, DARZALEX® (daratumumab) and Arzerra® (ofatumumab), and is developing a pipeline of antibody therapeutics for the treatment of cancer. Our clinical product pipeline includes  daratumumab, ofatumumab and tisotumab vedotin. In addition, we have several pre-clinical product candidates.

antibody batch

Products in development

Our antibodies are being evaluated in numerous clinical studies

20131108 Genmab produktfoto 120

Daratumumab

Our second approved product, first-in-class CD38 antibody for multiple myeloma

Ofatumumab

Our first approved product, also in development for other indications

Pre-clinical

Pre-clinical

Our pre-clinical product candidates help to fuel our future clinical pipeline